Business
Todos Medical Announces Publication in Journal of Clinical Virology Highlighting Clinical Utility of cPass Semi-Quantitative Neutralizing Antibody Test in SARS-CoV-2 Risk Assessment Post-Vaccination or Recovery from Infection
Todos Medical Announces Publication in Journal of Clinical Virology Highlighting Clinical Utility of cPass Semi-Quantitative Neutralizing Antibody Test in SARS-CoV-2 Risk Assessment Post-Vaccination or Recovery from Infection.
About this update from Todos Medical Ltd.
[{"type":"text","content":"\n Company hosting cPass webinar on Friday, October 22, 2021 for long-term care facilities New York, NY, and Tel Aviv, ISRAEL, Oct. 21, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced the publication of an article entitled “A Practical Approach to SARS-CoV-2 Testing in Pre and Post Vaccination Era” in the peer-reviewed Journal of Clinical Virology, available online at https://www.sciencedirect.com/science/article/pii/S2667038021000363?via%3Dihub , that highlights the clinical utility of combining the cPass neutralizing antibody test in the vaccinated and COVID-recovered populations with  PCR testing  in the unvaccinated and not previously infected to reduce COVID-19 transmission. Todos Medical is hosting a webinar entitled “New Paradigm for Measuring Immunity in Pre- and Post-Vaccination Era” on Friday, October 22nd, 2021 at 12:00pm ET for The Society for Post-Acute and Long-Term Care Medicine (“AMDA”), and is available for anyone to attend virtually on Todos’ YouTube Channel at: https://www.youtube.com/channel/UCWsJLl1iB9qlZUSicQ9e-Mg. The publication concluded, “To minimize the potential for future outbreaks, a revised testing strategy to assure initial and continued protection post-vaccination will likely be required. This could include a combination of qPCR (for non-vaccinated and susceptible people) and nAb (for previously infected and vaccinated people) assays. cPass sVNT could be a useful tool for substantiating individual immunity in a SARS-CoV-2 post-vaccination era.” Provista Dx offers high-throughput SARS-CoV-2 PCR testing and high-throughput semi-quantitative cPass neutralizing antibody testing as services. For more information on Provista’s testing services, please contact James Doherty, Sr. Director of Business Development at Provista Diagnostics at [email protected]. For more information, please visit www.todosmedical.com. For more information on the Company’s CLIA/CAP certified lab Provista Diagnostics, Inc. please visit www.provistadx.com. About Todos Medical Ltd. Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: T...